To outperform the Continental European market sector of companies of large and mid-size market capitalisation, while maintaining an adequate spread of risk.
Name | % Net Assets |
---|---|
Novartis | 3.7% |
Royal Dutch Petroleum | 3.6% |
Sanofi-Aventis | 3.4% |
UBS | 2.5% |
Total | 2.3% |
Koninklijke KPN | 2.1% |
E.ON AG | 2.1% |
Vivendi Universal | 2.0% |
ING Group | 1.9% |
Philips Electronics | 1.7% |
Key | % Net Assets |
---|---|
Novartis | 3.7% |
Royal Dutch Petroleum | 3.6% |
Sanofi-Aventis | 3.4% |
UBS | 2.5% |
Other | 86.8% |
Date | 23-Nov-2016 |
---|---|
NAV | 1,803.00p |
Currency | GBP |
Change | -1,503.90p |
% | -99.46% |
YTD change | 1,803.00p |
YTD % | n/a |
Fund Inception | 03/07/2000 |
---|---|
Fund Manager | Morgan Stanley Investment Mgt Ltd |
TER | - |
Minimum Investment | |
---|---|
Initial | £250000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 0.80% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.07 |
You are here: research